Non-target messenger RNAs with partial complementarity (Off-target mRNAs) (Off-target mRNAs)

Non-target messenger RNAs with partial complementarity refer to unintended genetic transcripts that are inadvertently silenced or regulated by oligonucleotide-based therapeutics, such as siRNAs, miRNAs, or ASOs. This phenomenon occurs when the therapeutic sequence shares enough homology with a non-target mRNA—often as little as a 6-7 nucleotide "seed" match—to facilitate binding and subsequent degradation or translational inhibition [1][2]. These off-target interactions are a primary concern in the development of RNA-targeted drugs, as they can lead to unpredictable cellular toxicity and side effects by disrupting essential biological pathways unrelated to the disease being treated [3]. Modern drug design strategies employ advanced bioinformatics and chemical modifications, such as 2'-O-methyl or locked nucleic acids, to increase specificity and reduce the affinity for these non-target sequences [4]. Understanding and predicting these interactions is vital for ensuring the safety and efficacy of precision genetic medicines [5].

Other names

Off-target transcriptsUnintended mRNA targetsSeed-match off-targetsPartial complementarity off-targets

Unintended silencing of gene expression through partial Watson-Crick base pairing, often mediated by the RNA-induced silencing complex (RISC) or RNase H, leading to mRNA degradation or translational repression [1][2].